Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,926
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.70 | 3.10 | 0.03% |
| CAC 40 | 8,112.02 | 8.44 | 0.10% |
| DAX 40 | 24,351.12 | 11.06 | 0.05% |
| Dow JONES (US) | 48,461.93 | 249.04 | -0.51% |
| FTSE 100 | 9,866.53 | 4.15 | -0.04% |
| HKSE | 25,635.23 | 183.70 | -0.71% |
| NASDAQ | 23,474.35 | 118.75 | -0.50% |
| Nikkei 225 | 50,526.92 | 223.47 | -0.44% |
| NZX 50 Index | 13,541.45 | 15.46 | 0.11% |
| S&P 500 | 6,905.74 | 24.20 | -0.35% |
| S&P/ASX 200 | 8,727.00 | 5.80 | 0.07% |
| SSE Composite Index | 3,965.28 | 1.60 | 0.04% |